STOCK TITAN

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Rhea-AI Summary

Dyne Therapeutics (DYN) granted inducement equity awards to 17 newly hired employees under Nasdaq Listing Rule 5635(c)(4). The grants comprise stock options to buy up to 213,000 common shares and restricted stock units covering 67,200 common shares.

The options have a ten-year term and an exercise price equal to Dyne’s closing share price on the Nasdaq Global Select Market on November 17, 2026. Both types of awards are scheduled to vest over four years, subject to continued employment through the applicable vesting dates. The grants are governed by the award agreements and Dyne’s 2024 Inducement Stock Incentive Plan.

Loading...
Loading translation...

Positive

  • None.

Negative

  • Minor point. Forward-looking: it has not happened yet and may not happen.Options to buy up to 213,000 common shares could dilute shareholders if exercised at the November 17, 2026, closing price.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Restricted stock units covering 67,200 common shares could dilute shareholders as shares are issued.

Key Figures

New hires: 17 employees Stock options: Up to an aggregate of 213,000 shares Restricted stock units: An aggregate of 67,200 shares +5 more
New hires
17 employees
Employees receiving inducement equity awards
Stock options
Up to an aggregate of 213,000 shares
Options to purchase common stock
Restricted stock units
An aggregate of 67,200 shares
Restricted stock unit awards
Option term
10 years
Stock options
Option vesting period
4 years
Subject to continued employee service
Initial option vesting
25%
On the first anniversary of the applicable employee’s start date
Subsequent option vesting
12 equal quarterly installments
After the first anniversary, subject to continued service
Restricted stock unit vesting
4 equal annual installments
Over four years from the applicable employee’s start date

Historical Context

2 past events · Latest: Oct 22
2 events
  1. Oct 22

    inducement grants

    24h Move
    -6.4%

    Prior grants covered options and RSUs for 16 hires under the same Nasdaq inducement rule.

  2. Sep 17

    inducement grants

    24h Move
    -5.3%

    Prior grants used four-year vesting and the same ten-year option term.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

non-statutory stock options, restricted stock units, nasdaq listing rule 5635(c)(4)
3 terms
non-statutory stock options financial
"non-statutory stock options to purchase up to an aggregate"
Non-statutory stock options are a type of reward that companies give to employees, allowing them to buy company shares at a set price within a certain period. Unlike formal or government-approved plans, these options are more flexible but may have different tax implications. For investors, they can influence a company's stock price and financial health, making them an important factor to consider.
restricted stock units financial
"restricted stock units with respect to an aggregate"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
nasdaq listing rule 5635(c)(4) regulatory
"in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

WALTHAM, Mass., Nov. 19, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to 17 newly hired employees. The awards were made as an inducement material to the newly hired employees’ acceptance of employment with Dyne in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement equity awards consisted of non-statutory stock options to purchase up to an aggregate of 213,000 shares of Dyne’s common stock at a per share exercise price equal to the closing price of Dyne’s common stock on The Nasdaq Global Select Market on November 17, 2026, and restricted stock units with respect to an aggregate of 67,200 shares of Dyne’s common stock. The stock options have a ten-year term and are scheduled to vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s start date and the remainder vesting in 12 equal quarterly installments thereafter, subject to such employee’s continued service to Dyne through the applicable vesting dates. The restricted stock units are scheduled to vest over four years from the applicable employee’s start date in four equal annual installments, subject to such employee’s continued service to Dyne through the applicable vesting dates.

The inducement equity awards are subject to the terms and conditions of award agreements covering the grants and Dyne’s 2024 Inducement Stock Incentive Plan.

About Dyne Therapeutics

Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD), Pompe disease and multiple DMD mutations. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.

Contacts:
Investors
Mia Tobias
ir@dyne-tx.com
781-317-0353

Media
Stacy Nartker
media@dyne-tx.com
781-317-1938


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity inducement awards did Dyne Therapeutics (DYN) grant to new employees?

Dyne granted options to buy up to 213,000 common shares and restricted stock units covering 67,200 common shares to 17 new hires. The option exercise price equals Dyne’s November 17, 2026, closing share price on the Nasdaq Global Select Market.

How do Dyne Therapeutics’ inducement options and restricted stock units vest?

The options begin vesting with 25% on the first anniversary of each employee’s start date, while the restricted stock units vest in four equal annual installments over four years from that date. The remaining options vest in 12 equal quarterly installments after the first anniversary. Both schedules require continued service through the applicable vesting dates.

Keep reading